<DOC>
	<DOCNO>NCT02519153</DOCNO>
	<brief_summary>Urolithiasis one common urological disease . The risk urolithiasis estimate 5 % 12 % world increase incidence male rather female ( 2:1 ) respectively . Ureteral stone account 20 % urinary tract stone , 70 % ureteral stone find low third ureter . The incidence urinary stone increase day day . Medical expulsive therapy ( MET ) ureteral stone investigator ' concern study . Stone location , size , number , ureteral spasm , mucosal edema inflammation ureteral anatomy factor affect passage ureteral stone . So , MET base mechanism stone passage facilitate relaxation ureteral smooth muscle , increase hydrostatic pressure proximal stone decrease excite edema . There many oral medication could use MET adrenergic blocker , calcium channel blocker , prostaglandin synthesis inhibitor , glyceryl trinitrate steroid treatment . Calcium-channel blocker adrenergic Î±-antagonists main propose enhance stone passage expulsive medical therapy . Cyclic nucleotides degraded phosphodiesterases enzyme ( PDEs ) . So use PDE inhibtors may play role relaxation smooth muscle ureter . A study do evaluation three PDE5 inhibtors , sildenafil , vardenafil tadalafil , find PDE5 inhibitor reverse tension isolate human ureteral smooth muscle via cGMP-mediated pathway .</brief_summary>
	<brief_title>Phosphodiesterase 5 Inhibitors ( PDE5i ) ( Sildenafil ) Medical Expulsive Therapy Distal Ureteral Stones</brief_title>
	<detailed_description />
	<mesh_term>Urolithiasis</mesh_term>
	<mesh_term>Ureteral Calculi</mesh_term>
	<mesh_term>Ureterolithiasis</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Male Patient age 1865 year . 2 . Lower third ureteric stone sacroiliac joint . 3 . Stone size ring 5 10 mm . 4 . Unilateral ureteric stone 1 . Patients recurrent fever . 2 . Patient underwent ESWL . 3 . Patient rise serum creatinine &gt; 2mg/dl . 4 . Patient history ureterovesical reimplantation . 5 . Stone large 10 mm</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Phosphodiesterase 5 Inhibitors</keyword>
	<keyword>PDE5i</keyword>
	<keyword>Sildinafil</keyword>
</DOC>